Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC

ALK (anaplastic lymphoma kinase) inhibitors may be used to treat patients with ALK mutant metastatic nonsmall cell cancer (NSCLC). This study aimed to investigate the factors affecting the patients response to treatment with ALK-positive metastatic NSCLC. Data of the patients were investigated retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Dogan, Izzet, Gurbuz, Mustafa, Paksoy, Nail, Ferhatoglu, Ferhat, Vatansever, Sezai, Saip, Pinar, Demirkazik, Ahmet, Aydiner, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410652/
https://www.ncbi.nlm.nih.gov/pubmed/36042659
http://dx.doi.org/10.1097/MD.0000000000030188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410652/
https://www.ncbi.nlm.nih.gov/pubmed/36042659
http://dx.doi.org/10.1097/MD.0000000000030188

Ejemplares similares